A Formulation and Evaluation of Gastro-retentive In-Situ Gel of Anti-Ulcer Drug Misoprostol

Lucky Vasave; Shivraj Jadhav; Rushikesh Bachhav; Sunil Mahajan; Deepak Sonawane

doi:10.56782/pps.441

Published : 2025-08-07

No. 2025 (Early Access)

A Formulation and Evaluation of Gastro-retentive In-Situ Gel of Anti-Ulcer Drug Misoprostol

Lucky Vasave

Shivraj Jadhav

Rushikesh Bachhav

Sunil Mahajan

Deepak Sonawane

DOI: https://doi.org/10.56782/pps.441

Abstract

Background: Peptic ulcer disease (PUD) is a prevalent gastrointestinal disorder caused by an imbalance between protective and aggressive gastric factors. Misoprostol, a synthetic prostaglandin E1 analogue, is effective in ulcer management but has limitations such as rapid metabolism, low bioavailability, and frequent dosing. This study aimed to develop a gastro-retentive in-situ gel of misoprostol to enhance gastric retention and controlled drug release. Methods: The in-situ gel was formulated using gellan gum and calcium carbonate as key excipients. A 3² factorial design was employed to optimize floating lag time and in-vitro drug release. The formulations were evaluated for pH, viscosity, gelling capacity, floating behavior, drug content, and in-vitro drug release using a USP Type II dissolution apparatus in simulated gastric fluid (pH 1.2). Stability studies were conducted under accelerated conditions (40°C ± 2°C / 75% ± 5% RH) for six months. Results: The optimized formulation (LF5) exhibited a pH of 6.6, a floating lag time of 18.03 seconds, and a total floating time exceeding 6 hours, ensuring prolonged gastric retention. Drug content analysis confirmed 93.04% uniformity across batches. In-vitro drug release showed sustained drug release of 93.04% over 240 minutes. Stability studies demonstrated no significant changes in pH, floating behavior, or drug content, confirming formulation robustness. Conclusion: The gastro-retentive in-situ gel of misoprostol successfully enhanced gastric retention and controlled drug release. The optimized formulation exhibited rapid buoyancy, prolonged retention, and stability, making it a promising approach for improving misoprostol’s therapeutic efficacy in peptic ulcer management.

Keywords:

Peptic ulcer disease, Gastro-retentive in-situ gel, Misoprostol, Gellan gum, Calcium carbonate, Floating drug delivery, Controlled release, Stability study

Similar Articles

Falah Saleh Mohammed, Eylem Kına, İmran Uysal, Mustafa Sevindik, Total phenolic, flavonoid contents, antioxidant and antimicrobial activities of Hesperis pendula , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Esraa Alkhalil, Bashar Jarad, Tala Saleh, Wafaa Aldarwish, Dr. Dima Joujeh, BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety , Prospects in Pharmaceutical Sciences: Vol. 23 No. 1 (2025)
Kinga Sosnowicz, Monika Czerwińska, Plant materials used in eye diseases - from use in traditional medicine to research in antioxidant, anti - inflammatory, and antibacterial activity , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

<< < 14 15 16 17 18 19

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Vasave, L., Jadhav, S., Bachhav, R., Mahajan, S., & Sonawane, D. (2025). A Formulation and Evaluation of Gastro-retentive In-Situ Gel of Anti-Ulcer Drug Misoprostol. Prospects in Pharmaceutical Sciences, (2025 (Early Access). https://doi.org/10.56782/pps.441

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

(1) Yegen, B. C. Lifestyle and Peptic Ulcer Disease. CPD 2018, 24 (18), 2034–2040. DOI:10.2174/1381612824666180510092303. DOI: https://doi.org/10.2174/1381612824666180510092303

(2) Xie, X.; Ren, K.; Zhou, Z.; Dang, C.; Zhang, H. The Global, Regional and National Burden of Peptic Ulcer Disease from 1990 to 2019: A Population-Based Study. BMC Gastroenterol 2022, 22 (1), 58. DOI:10.1186/s12876-022-02130-2. DOI: https://doi.org/10.1186/s12876-022-02130-2

(3) Shell, E. J. Pathophysiology of Peptic Ulcer Disease. PA Clinics 2021, 6 (4), 603–611. DOI:10.1016/j.cpha.2021.05.005. DOI: https://doi.org/10.1016/j.cpha.2021.05.005

(4) Srivastav, Y.; Kumar, V.; Srivastava, Y.; Kumar, M. Peptic Ulcer Disease (PUD), Diagnosis, and Current Medication-Based Management Options: Schematic Overview. JAMPS 2023, 25 (11), 14–27. DOI:10.9734/jamps/2023/v25i11651. DOI: https://doi.org/10.9734/jamps/2023/v25i11651

(5) Lee, S. P.; Sung, I.-K.; Kim, J. H.; Lee, S.-Y.; Park, H. S.; Shim, C. S. Risk Factors for the Presence of Symptoms in Peptic Ulcer Disease. Clin Endosc 2017, 50 (6), 578–584. DOI:10.5946/ce.2016.129. DOI: https://doi.org/10.5946/ce.2016.129

(6) Dunlap, J. J.; Patterson, S. Peptic Ulcer Disease. Gastroenterol Nur 2019, 42 (5), 451–454. DOI:10.1097/SGA.0000000000000478. DOI: https://doi.org/10.1097/SGA.0000000000000478

(7) Vigani, B.; Rossi, S.; Sandri, G.; Bonferoni, M. C.; Caramella, C. M.; Ferrari, F. Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes. Pharmaceutics 2020, 12 (9), 859. DOI:10.3390/pharmaceutics12090859. DOI: https://doi.org/10.3390/pharmaceutics12090859

(8) Bilal Jilani Shaikh; Indrayani D Raut; Manojkumar M Nitalikar; Shrinivas K. Mohite; Chandrakant S. Magdum. An Overview on In-Situ Gel: A Novel Drug Delivery System. Int J Pharm Sci Nanotechnol 2021, 15 (5), 6180–6189. DOI:10.37285/ijpsn.2022.15.5.10. DOI: https://doi.org/10.37285/ijpsn.2022.15.5.10

(9) Wu, Y.; Liu, Y.; Li, X.; Kebebe, D.; Zhang, B.; Ren, J.; Lu, J.; Li, J.; Du, S.; Liu, Z. Research Progress of In-Situ Gelling Ophthalmic Drug Delivery System. Asian J Pharm Sci 2019, 14 (1), 1–15. DOI:10.1016/j.ajps.2018.04.008. DOI: https://doi.org/10.1016/j.ajps.2018.04.008

(10) Kamada, T.; Satoh, K.; Itoh, T.; Ito, M.; Iwamoto, J.; Okimoto, T.; Kanno, T.; Sugimoto, M.; Chiba, T.; Nomura, S.; Mieda, M.; Hiraishi, H.; Yoshino, J.; Takagi, A.; Watanabe, S.; Koike, K. Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2020. J Gastroenterol 2021, 56 (4), 303–322. DOI:10.1007/s00535-021-01769-0. DOI: https://doi.org/10.1007/s00535-021-01769-0

(11) Jadhav, S. P.; Dhakad, P. K.; Gupta, T.; Gilhotra, R. Formulation Development and Evaluation of Paliperidone Nanosuspension for Solubility Enhancement. Int J App Pharm 2024, 173–181. DOI:10.22159/ijap.2024v16i4.51218. DOI: https://doi.org/10.22159/ijap.2024v16i4.51218

(12) Wu, H.; Marwah, S.; Wang, P.; Wang, Q.; Chen, X. Misoprostol for Medical Treatment of Missed Abortion: A Systematic Review and Network Meta-Analysis. Sci Rep 2017, 7 (1), 1664. DOI:10.1038/s41598-017-01892-0. DOI: https://doi.org/10.1038/s41598-017-01892-0

(13) Raymond, E. G.; Harrison, M. S.; Weaver, M. A. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019, 133 (1), 137–147. DOI:10.1097/AOG.0000000000003017. DOI: https://doi.org/10.1097/AOG.0000000000003017

(14) Salzberger, H.; Maul, H. Gutes Misoprostol, böses Misoprostol – oder wie ich es schaffe, ein Medikament mehr als 100-mal teurer zu machen? Geburtshilfe Frauenheilkd 2022, 82 (05), 480–486. DOI:10.1055/a-1664-0036. DOI: https://doi.org/10.1055/a-1664-0036

(15) Szpot, P.; Wachełko, O.; Zawadzki, M. Determination of Prostaglandins (Carboprost, Cloprostenol, Dinoprost, Dinoprostone, Misoprostol, Sulprostone) by UHPLC-MS/MS in Toxicological Investigations. Toxics 2023, 11 (10), 802. DOI:10.3390/toxics11100802. DOI: https://doi.org/10.3390/toxics11100802

(16) Da Silva, J. W. V.; Duarte, M. L.; Ribeiro, J. I.; Kishishita, J.; Souza, A. T. M.; Leal, L. B.; De Castro, W. V.; De Santana, D. P.; Bedor, D. C. G. Development and Validation of a Stability‐indicating Method, Structural Elucidation of New Degradation Products from Misoprostol by LC–MS Time‐of‐flight, and an Ex Vivo Study of Vaginal Permeation. Biomed Chromatogr 2024, 38 (8), e5897. DOI:10.1002/bmc.5897. DOI: https://doi.org/10.1002/bmc.5897

(17) Rojek, B.; Wesolowski, M. A Combined Differential Scanning Calorimetry and Thermogravimetry Approach for the Effective Assessment of Drug Substance-Excipient Compatibility. J Therm Anal Calorim 2023, 148 (3), 845–858. DOI:10.1007/s10973-022-11849-9. DOI: https://doi.org/10.1007/s10973-022-11849-9

(18) Załuski, D.; Dubis, B.; Budzyński, W.; Jankowski, K. Applicability of the 35–2 Fractional Factorial Design in Determining the Effects of Cultivation Factors on Hulless Oat. Agronomy 2016, 108 (1), 205–218. DOI:10.2134/agronj2014.0607. DOI: https://doi.org/10.2134/agronj2014.0607

(19) M, S. S.; Priya, S.; Maxwell, A. Formulation and Evaluation of Novel in Situ Gel of Lafutidine for Gastro-Retentive Drug Delivery. Asian J Pharm Clin Res 2018, 11 (8), 88. DOI:10.22159/ajpcr.2018.v11i8.25582. DOI: https://doi.org/10.22159/ajpcr.2018.v11i8.25582

(20) S. N. Shaikh; V. G. Jain; G. J. Khan. Design, Development and Evaluation of Gastric Floating in-Situ Gel of Piroxicam. IJPSR 11 (7).

(21) Juthi, A. Z.; Li, F.; Wang, B.; Alam, M. M.; Talukder, M. E.; Qiu, B. pH-Responsive Super-Porous Hybrid Hydrogels for Gastroretentive Controlled-Release Drug Delivery. Pharmaceutics 2023, 15 (3), 816. DOI:10.3390/pharmaceutics15030816. DOI: https://doi.org/10.3390/pharmaceutics15030816

(22) R., V.; Priya, S.; Jyothi, D.; James, J. P. Formulation and Evaluation of Novel in Situ Gel of Lafutidine for Gastro-Retentive Drug Delivery. Int J App Pharm 2024, 76–85. DOI:10.22159/ijap.2024v16i2.49033.

(23) Soni, A.; Mahesh Kumar Kataria. Formulation and Evaluation of Floating in Situ Gel of Omeprazole Magnesium for Oral Drug Delivery System. Asian J Pharm Clin Res 2021, 44–52. DOI:10.22159/ajpcr.2021.v14i9.42231. DOI: https://doi.org/10.22159/ajpcr.2021.v14i9.42231

(24) Siripruekpong, W.; Praparatana, R.; Issarachot, O.; Wiwattanapatapee, R. Simultaneous Delivery of Curcumin and Resveratrol via In Situ Gelling, Raft-Forming, Gastroretentive Formulations. Pharmaceutics 2024, 16 (5), 641. DOI:10.3390/pharmaceutics16050641. DOI: https://doi.org/10.3390/pharmaceutics16050641

(25) Mahmoud, D. B.; Shukr, M. H.; ElMeshad, A. N. Gastroretentive Cosolvent-Based In Situ Gel as a Promising Approach for Simultaneous Extended Delivery and Enhanced Bioavailability of Mitiglinide Calcium. Journal of Pharmaceutical Sciences 2019, 108 (2), 897–906. DOI:10.1016/j.xphs.2018.09.020.

(26) Kathpalia, H.; Salunkhe, S.; Juvekar, S. Formulation of Gastroretentive Sustained Release Floating in Situ Gelling Drug Delivery System of Solubility Enhanced Curcumin-Soy Lecithin Complex. J Drug Del Sci Tech 2019, 53, 101205. DOI:10.1016/j.jddst.2019.101205.

(27) Shabaraya, Ar.; T Ashwini, T.; Vineetha, K. Formulation and Evaluation of Gastroretentive In Situ Gelling System of Ketoprofen. Eur Pharm J 2023, 70 (2), 10–19. DOI:10.2478/afpuc-2023-0018. DOI: https://doi.org/10.2478/afpuc-2023-0018

(28) Malviya, V.; Tawar, M.; Burange, P.; Bairagi, R. Preparation and Characterization of Gastroreten-Tive Sustained Release In-Situ Gel of Lafutidine. IJPSN 2022, 15 (6), 6216–6228. DOI:10.37285/ijpsn.2022.15.6.4. DOI: https://doi.org/10.37285/ijpsn.2022.15.6.4

(29) Mahmoud, D. B.; Shukr, M. H.; ElMeshad, A. N. Gastroretentive Cosolvent-Based In Situ Gel as a Promising Approach for Simultaneous Extended Delivery and Enhanced Bioavailability of Mitiglinide Calcium. J Pharm Sci 2019, 108 (2), 897–906. DOI:10.1016/j.xphs.2018.09.020. DOI: https://doi.org/10.1016/j.xphs.2018.09.020

(30) vijayashree R.; Divya Jyothi; Jainey P. James. Formulation and Characterisation of Gastroretentive in Situ Gel Loaded with Glycyrrhiza Glabra L. Extract for Gastric Ulcer. Int J App Pharm 2024, 76–85. DOI:10.22159/ijap.2024v16i2.49033. DOI: https://doi.org/10.22159/ijap.2024v16i2.49033

(31) Department of Biological Science, Faculty of Science and Technology, Bingham University, Karu, Nigeria; Anyanwu, N. Development and Evaluation of in Situ Gelling Gastroretentive Formulations of Meloxicam. UJPR 2017, 2 (3), 11–14. DOI:10.22270/ujpr.v2i3.R3. DOI: https://doi.org/10.22270/ujpr.v2i3.R3

(32) Kim, J. H.; Song, S. H.; Joo, S. H.; Park, G. H.; Weon, K.-Y. Formulation of a Gastroretentive In Situ Oral Gel Containing Metformin HCl Based on DoE. Pharmaceutics 2022, 14 (9), 1777. DOI:10.3390/pharmaceutics14091777. DOI: https://doi.org/10.3390/pharmaceutics14091777

(33) Kathpalia, H.; Salunkhe, S.; Juvekar, S. Formulation of Gastroretentive Sustained Release Floating in Situ Gelling Drug Delivery System of Solubility Enhanced Curcumin-Soy Lecithin Complex. J Drug Del Sci Tech 2019, 53, 101205. DOI:10.1016/j.jddst.2019.101205. DOI: https://doi.org/10.1016/j.jddst.2019.101205

A Formulation and Evaluation of Gastro-retentive In-Situ Gel of Anti-Ulcer Drug Misoprostol

Lucky Vasave

Shivraj Jadhav

Rushikesh Bachhav

Sunil Mahajan

Deepak Sonawane

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Lucky Vasave

Shivraj Jadhav

Rushikesh Bachhav

Sunil Mahajan

Deepak Sonawane